Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Joseph Kim, MD
Advertisement
Articles by Joseph Kim, MD
Joseph Kim, MD, discusses the multidisciplinary management of hepatocellular carcinoma.
Joseph Kim, MD, discusses the evolution of therapy in metastatic hepatocellular carcinoma.
Joseph Kim, MD, discusses curative therapeutic options in hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCCDecember 21st 2020
Dr. Kim on the Multidisciplinary Management of HCCDecember 15th 2020
Dr. Kim on the Evolution of Therapy in Metastatic HCCDecember 1st 2020
Dr. Kim on Curative Treatment Options in HCCNovember 25th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5